Skip to main content
    H

    Hoth Therapeutics Inc (HOTH)

    Official site

    BIOTECHNOLOGY

    $0.32
    -0.02 (-7.01%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Hoth Therapeutics Inc (HOTH) Financials: Revenue, Profit and Cash Flow

    Updated Mar 31, 2026. Financial statements from company filings, amounts in US dollars.

    Hoth Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$12.47M, operating cash flow was -$9.80M and free cash flow was -$9.80M. The quarter ended Mar 31, 2026 had revenue of $0 and net income of -$2.69M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $11.11M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Mar 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Cost of revenueN/AN/AN/A$66.83K$46.87M$25.87K$31.62K$28.25K$188
    Gross profitN/AN/AN/A-$66.83K-$46.87M-$25.87K-$31.62K-$28.25K-$188
    Research and development$5.95M$3.25M$3.48M$4.93M$7.53M$2.89M$2.12M$1.02M$586.84K
    Operating income-$11.11M-$8.22M-$7.69M-$11.07M-$14.10M-$7.30M-$7.71M-$2.50M-$1.87M
    Net income-$12.47M-$8.19M-$7.85M-$11.37M-$14.31M-$7.20M-$7.69M-$2.50M-$2.02M
    EBITDA-$11.11M$27.13K-$153.15K-$10.68MN/A-$7.30M-$7.71M-$2.49MN/A
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Revenue$0$0$0$0$0$0$0$0$0$59.54K$0$0
    Gross profitN/AN/AN/AN/A-$4.35KN/AN/AN/AN/A$29.77K-$6.75K-$7.90K
    Operating income-$2.65M-$2.61M-$4.08M-$2.20M-$3.48M-$2.38M-$2.13M-$1.65M-$2.16M-$1.70M-$2.09M-$1.71M
    Net income-$2.69M-$2.69M-$4.11M-$2.20M-$3.48M-$2.38M-$2.13M-$1.63M-$2.15M-$1.70M-$2.09M-$1.87M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $5.68K by $6.24M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$7.60M$7.71M$10.24M$6.76M$10.99M$5.24M$2.84M$503.92K$1.23M
    Current assets$6.86M$7.64M$10.15M$6.73M$10.58M$4.78M$2.64M$501.65K$1.23M
    Cash and equivalents$6.25M$7.04M$9.29M$6.43M$8.54M$2.63M$1.69M$282.62K$1.23M
    Total liabilities$1.45M$833.91K$704.98K$1.64M$1.10M$597.15K$440.12K$348.95K$49.47K
    Short-term debt$5.68K$28.37K$28.84KN/AN/AN/AN/AN/AN/A
    Shareholder equity$6.15M$6.88M$9.54M$5.12M$9.88M$4.65M$2.40M$154.97K$1.18M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total assets$5.59M$7.60M$9.24M$10.11M$12.36M$7.71M$8.31M$10.03M$8.49M$10.24M$12.09M$11.92M
    Total liabilities$1.43M$1.45M$1.01M$364.63K$815.30K$833.91K$813.03K$691.86K$658.74K$704.98K$1.58M$1.97M
    Cash and equivalents$4.05M$6.25M$7.85M$9.01M$11.32M$7.04M$8.02M$9.65M$7.56M$9.29M$11.83M$11.54M
    Shareholder equity$4.16M$6.15M$8.23M$9.74M$11.54M$6.88M$7.49M$9.34M$7.83M$9.54M$10.51M$9.95M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$9.80M-$6.98M-$8.45M-$9.30M-$12.09M-$6.13M-$4.95M-$2.10M-$465.24K
    Capital expenditures$0$0$4$74.00K$116.97K$167.46K$95.00K$0$303.68K
    Free cash flow-$9.80M-$6.98M-$8.45M-$9.37M-$12.21M-$6.30M-$5.04M-$2.10M-$768.92K
    Investing cash flow-$300.00KN/AN/A$1.16M-$165.35K-$1.84M-$895.00K-$895.00K-$303.68K
    Financing cash flow$9.31M$4.74M$11.32M$6.04M$18.19M$8.73M$7.45M$1.15M$2.00M
    Fiscal years ended Dec 2017 to Dec 2025

    Quarterly

    Line itemMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Operating cash flow-$3.05M-$2.15M-$2.49M-$2.37M-$2.79M-$2.03M-$1.63M-$1.59M-$1.72M-$3.07M-$1.64M-$1.45M
    Capital expenditures$3$5$2$5$5$4$4$5$0$0$0$3
    Free cash flow-$3.05M-$2.15M-$2.49M-$2.37M-$2.79M-$2.03M-$1.63M-$1.59M-$1.72M-$3.07M-$1.64M-$1.45M
    Last 12 quarters

    Frequently Asked Questions About HOTH

    What is Hoth Therapeutics' annual revenue?

    Hoth Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Hoth Therapeutics profitable?

    No. Hoth Therapeutics reported net income of -$12.47M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does HOTH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$9.80M minus capital expenditures of $0 produced free cash flow of -$9.80M.

    How much debt does Hoth Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $5.68K and cash and equivalents of $6.25M.